A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Trial ID or NCT#

NCT00250432,

Status

not recruiting iconNOT RECRUITING

Purpose

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Official Title

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Clinical and Laboratory evidence of blood stream \&/or systemic candida infections
Exclusion Criteria:
  1. * Possible candida contamination* Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections* Acute or moderately severe liver disease* Abnormal liver function tests* Abnormal blood clotting for patients on blood thinners
View All Criteria
Show Less

Investigator(s)

Dora Ho
Dora Ho
Infectious diseases doctor
Clinical Professor, Medicine - Infectious Diseases

Contact us to find out if this trial is right for you.

Contact

Joanna Schaenman

View on ClinicalTrials.gov